BETA ZEN
25T7-NBOMe
Texto da Wikipédia (en), licença CC BY-SA. O BETARUBI mostra o verbete inteiro nesta página — a leitura não continua fora do site.
 | |
| Clinical data | |
|---|---|
| Other names | 2C-T-7-NBOMe; NBOMe-2C-T-7; N-(2-Methoxybenzyl)-4-propylthio-2,5-dimethoxyphenethylamine |
| Drug class | Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H29NO3S |
| Molar mass | 375.53 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
25T7-NBOMe, also known as 2C-T-7-NBOMe or NBOMe-2C-T-7 as well as N-(2-methoxybenzyl)-4-propylthio-2,5-dimethoxyphenethylamine, is a serotonergic psychedelic of the 25-NB (NBOMe) family. It is the NBOMe analogue of 2C-T-7. The compound has been sold as a designer drug.[2][3][4][5][6]
Use and effects
The active dose range and route of 25T7-NBOMe do not appear to have been described.[7]
Interactions
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 1,800–>10,000 |
| 5-HT1B | 1,902–>10,000 |
| 5-HT1D | 1,349–2,176 |
| 5-HT1E | >10,000 |
| 5-HT1F | ND |
| 5-HT2A | 0.68–1.16 (Ki) 7.42–260 (EC50) 41–173% (Emax) |
| 5-HT2B | 2.16–2.3 (Ki) 310 (EC50) 14% (Emax) |
| 5-HT2C | 1.33–6.4 (Ki) 19.1 (EC50) 95% (Emax) |
| 5-HT3 | >10,000 |
| 5-HT4 | ND |
| 5-HT5A | >10,000 |
| 5-HT6 | 62.4–68.8 |
| 5-HT7 | >10,000 |
| α1A | 340–490 |
| α1B | >10,000 |
| α1D | 1,429 |
| α2A | 226–360 |
| α2B | 603 |
| α2C | 479 |
| β1 | ND |
| β2 | 4,266 |
| β3 | 2,163 |
| D1 | 4,100 |
| D2 | 1,000 |
| D3 | 153–1,400 |
| D4 | 186 |
| D5 | ND |
| H1 | 403–1,200 |
| H2 | 1,000 |
| H3–H4 | ND |
| M1–M5 | ND |
| I1 | ND |
| σ1 | 19.1 |
| σ2 | 22.6 |
| MOR | 944 |
| DOR | >10,000 |
| KOR | 148 |
| TAAR1 | 1,000 (Ki) (mouse) 88–90 (Ki) (rat) 2,100 (EC50) (mouse) 550 (EC50) (rat) >10,000 (EC50) (human) 68% (Emax) (mouse) 52% (Emax) (rat) |
| SERT | 1,514–3,200 (Ki) 17,000 (IC50) ND (EC50) |
| NET | 3,700–>10,000 (Ki) 34,000 (IC50) ND (EC50) |
| DAT | 2,344 (Ki) 55,000 (IC50) ND (EC50) |
| Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [8][9][10][2][3][11][12] | |
25T7-NBOMe acts as a highly potent and selective agonist of the serotonin 5-HT2 receptors.[2] Its affinities and activities at a variety of other receptors and transporters have also been described.[2]
History
25T7-NBOMe was first described in the scientific literature by 2012.[13]
Society and culture
Legal status
Canada
25T7-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.[14]
See also
References
- ↑ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
- 1 2 3 4 Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)" (PDF). Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. PMID 26318099.
- 1 2 Pottie E, Poulie CB, Simon IA, Harpsøe K, D'Andrea L, Komarov IV, et al. (August 2023). "Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists". ACS Chemical Neuroscience. 14 (15): 2727–2742. doi:10.1021/acschemneuro.3c00267. PMC 10401645. PMID 37474114.
- ↑ Botch-Jones S, Foss J, Barajas D, Kero F, Young C, Weisenseel J (October 2016). "The detection of NBOMe designer drugs on blotter paper by high resolution time-of-flight mass spectrometry (TOFMS) with and without chromatography". Forensic Science International. 267: 89–95. doi:10.1016/j.forsciint.2016.08.008. PMID 27572638.
- ↑ Grumann C, Auwärter V (February 2018). "Separation of positional isomers of nine 2-phenethylamine-derived designer drugs by liquid chromatography-tandem mass spectrometry". Drug Testing and Analysis. 10 (7): 1184–1191. doi:10.1002/dta.2371. PMID 29455470.
- ↑ Fan SY, Zang CZ, Shih PH, Ko YC, Hsu YH, Lin MC, et al. (August 2021). "Simultaneous LC-MS/MS screening for multiple phenethylamine-type conventional drugs and new psychoactive substances in urine". Forensic Science International. 325 110884. doi:10.1016/j.forsciint.2021.110884. PMID 34245937. S2CID 235791505.
- ↑ Luethi D, Liechti ME (October 2018). "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". Int J Neuropsychopharmacol. 21 (10): 926–931. doi:10.1093/ijnp/pyy047. PMC 6165951. PMID 29850881.
- ↑ i</sub> values for 25T7-NBOMe"},"work":{"wt":"Psychoactive Drug Screening Program (PDSP)"},"publisher":{"wt":"University of North Carolina at Chapel Hill"},"date":{"wt":"15 July 2025"},"url":{"wt":"https://pdspdb.unc.edu/kidb2/kidb/web/kis-results/index?KisResultsSearch%5Binput_receptors%5D=&KisResultsSearch%5Binput_sources%5D=&KisResultsSearch%5Binput_species%5D=&KisResultsSearch%5Binput_hot_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D%5B%5D=14688&KisResultsSearch%5Binput_citations%5D=&KisResultsSearch%5BsearchType%5D=&KisResultsSearch%5Bki_val_from%5D=&KisResultsSearch%5Bki_val_to%5D=&KisResultsSearch%5Bcustom_ki_val%5D=&KisResultsSearch%5Binput_receptors%5D=&KisResultsSearch%5Binput_sources%5D=&KisResultsSearch%5Binput_species%5D=&KisResultsSearch%5Binput_hot_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D=&KisResultsSearch%5Binput_test_ligands%5D%5B%5D=14689&KisResultsSearch%5Binput_citations%5D=&KisResultsSearch%5BsearchType%5D=&KisResultsSearch%5Bki_val_from%5D=&KisResultsSearch%5Bki_val_to%5D=&KisResultsSearch%5Bcustom_ki_val%5D="},"access-date":{"wt":"15 July 2025"}},"i":0}}]}' id="mwAjI"/>"Ki values for 25T7-NBOMe". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill. 15 July 2025. Retrieved 15 July 2025.
- ↑ Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
- ↑ Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, et al. (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–249. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.
- ↑ Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1" (PDF). J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601. Archived from the original (PDF) on 2025-05-09.
- ↑ Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, et al. (July 2025). "The polypharmacology of psychedelics reveals multiple targets for potential therapeutics" (PDF). Neuron. 113 (19): 3129–3142.e9. doi:10.1016/j.neuron.2025.06.012. PMID 40683247.
- ↑ Casale JF, Hays PA (2012). "Characterization of eleven 2, 5-dimethoxy-N-(2-methoxybenzyl) phenethylamine (NBOMe) derivatives and differentiation from their 3-and 4-methoxybenzyl analogues—part I." (PDF). Microgram Journal. 9 (2): 84–109.
- ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.